Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9326MR)

This product GTTS-WQ9326MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF18 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_004195.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8784
UniProt ID Q9Y5U5
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9326MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1893MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AGEN2034
GTTS-WQ1944MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGS15C
GTTS-WQ6776MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DS-1062
GTTS-WQ6751MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DS 992
GTTS-WQ11187MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI0562
GTTS-WQ11440MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ4285MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BIIB-054
GTTS-WQ879MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-181
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW